1. Home
  2. FBGL vs KPRX Comparison

FBGL vs KPRX Comparison

Compare FBGL & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FBGL

FBS Global Limited Ordinary Shares

HOLD

Current Price

$0.53

Market Cap

11.3M

ML Signal

HOLD

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

HOLD

Current Price

$2.54

Market Cap

11.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FBGL
KPRX
Founded
1996
1998
Country
Singapore
United States
Employees
N/A
13
Industry
Miscellaneous manufacturing industries
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.3M
11.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FBGL
KPRX
Price
$0.53
$2.54
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
251.0K
16.4K
Earning Date
05-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$1.76
52 Week High
$1.40
$3.06

Technical Indicators

Market Signals
Indicator
FBGL
KPRX
Relative Strength Index (RSI) 44.51 48.01
Support Level $0.51 $2.44
Resistance Level $0.66 $2.61
Average True Range (ATR) 0.07 0.09
MACD -0.00 -0.00
Stochastic Oscillator 32.10 71.43

Price Performance

Historical Comparison
FBGL
KPRX

About FBGL FBS Global Limited Ordinary Shares

FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and Sales of construction materials.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: